We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sanofi | EU:SAN | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.60 | -0.65% | 91.30 | 91.12 | 91.90 | 92.24 | 91.09 | 91.83 | 891,417 | 16:40:00 |
By Chris Wack
Translate Bio Inc. shares were up 12% to $11.50 after the company said the U.S. Food and Drug Administration has granted rare pediatric disease designation for MRT5005 for the treatment of cystic fibrosis.
MRT5005 is designed to deliver mRNA encoding fully functional cystic fibrosis transmembrane conductance regulator protein to cells in the lung through nebulization.
The therapeutics company said it anticipates Covid-19-related interruptions in enrollment, dosing and follow-up in the ongoing phase 1/2 clinical trial in patients with cystic fibrosis. The company will provide updated timing on the expected interim data readout of the additional single-ascending dose group and the multiple-ascending dose portion of the clinical trial at a later date.
TranslateBio also said it was working with French pharmaceutical company Sanofi SA to develop a new mRNA vaccine candidate against Covid-19, the disease caused by the new coronavirus.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 27, 2020 07:49 ET (11:49 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions